| Only therapy specifically approved for the prevention of headaches in adults with CM in the EU |
| Therapy involves regular (3-monthly) injections |
| Efficacy and tolerability in large clinical trials confirmed in large real-world studies |
| Beneficial in patients regardless of whether or not they are acute medication overusers |
| Neck pain, (facial-) muscle weakness and eyelid ptosis are the most common treatment-related adverse events |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.